UPDATE: APPLICATION COMPLETED

ADVANCING THE UNDERSTANDING OF TYPE 1 DIABETES PATHOGENESIS (BIOSAMPLES PROVIDED FROM A PRIMARY PREVENTION TRIAL)

Launched in late 2017, the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) is designed to carry out newborn screening in the general population, identify infants at high genetic risk of developing type 1 diabetes, and offer them participation in trials to prevent disease initiation.

The Primary Oral Insulin Trial (POInT), GPPAD’s first randomized controlled clinical trial, is designed to determine if administration of high dose oral insulin can prevent the initiation of type 1 diabetes-related autoimmunity in young children at high genetic risk. GPPAD completed enrollment of POInT in early 2021, with 1,050 participants enrolled, 94 of whom have developed type 1 diabetes-related  autoantibodies. In addition to biosamples collected for trial purposes, an array of additional biosamples (serum, plasma, RNA, whole blood, PBMC, stool), which can be connected to relevant clinical data, are collected at multiple timepoints from 90% of POInT participants and biobanked.

We are now announcing a Request For Proposal (RFP) for investigators to perform innovative research on biosamples from the GPPAD POInT clinical trial utilizing cutting-edge analysis techniques relevant to pancreatic, metabolic or immune research, which complement ongoing research approaches and analyses being carried out by GPPAD.

For more information see this document Request For Proposal (RFP)

All information about the availability of samples and data can be found HERE

Direct scientific and application-related questions please contact GPPAD Central Office.